English

Intra-Cellular Therapies, Inc.

EDGAR

ITCI Annual report amendment (10-K/A) · filed 2025-03-20

Annual consolidated revenue for 2024: about USD 680.9M, using the latest reported figures. The previous period, 2023, was about USD 464.4M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

199 million USD

2024 Q4 · USD

Exact inputs and evidence

Revenue: 199223000 USD Source

Operating margin

-14.66%

2024 Q4 · %

Exact inputs and evidence

Operating Income: -116721000 USD Source
Operating Income: -87524000 USD Source
Revenue: 199223000 USD Source

Operating cash flow

-13.1 million USD

2024 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -73177000 USD Source
Operating Cash Flow: -60099000 USD Source

Cash and cash equivalents: 307 million USD 2024-12-31 Source
Exact value

306948000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 106 million shares 2024-12-31 Source
Exact value

106240009 shares

Reported share-count change

10.23% · 9.86 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

96379811 shares · 2023-12-31· Source
106240009 shares · 2024-12-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

681 million USD

2024-01-01 – 2024-12-31

Exact inputs and evidence

Revenue: 144866000 USD · 2024-01-01 – 2024-03-31 Source
Revenue: 161388000 USD · 2024-04-01 – 2024-06-30 Source
Revenue: 175375000 USD · 2024-07-01 – 2024-09-30 Source
Revenue: 199223000 USD · 2024-10-01 – 2024-12-31 Source

Net income

-74.7 million USD

2024-01-01 – 2024-12-31

Exact inputs and evidence

Net income: -15247000 USD · 2024-01-01 – 2024-03-31 Source
Net income: -16220000 USD · 2024-04-01 – 2024-06-30 Source
Net income: -26324000 USD · 2024-07-01 – 2024-09-30 Source
Net income: -16885000 USD · 2024-10-01 – 2024-12-31 Source

Operating cash flow

-73.2 million USD

2024-01-01 – 2024-12-31

Exact inputs and evidence

Operating cash flow: -34116000 USD · 2024-01-01 – 2024-03-31 Source
Operating cash flow: -33574000 USD · 2024-01-01 – 2024-06-30 Source
Operating cash flow: -34116000 USD · 2024-01-01 – 2024-03-31 Source
Operating cash flow: -60099000 USD · 2024-01-01 – 2024-09-30 Source
Operating cash flow: -33574000 USD · 2024-01-01 – 2024-06-30 Source
Operating cash flow: -73177000 USD · 2024-01-01 – 2024-12-31 Source
Operating cash flow: -60099000 USD · 2024-01-01 – 2024-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2025-03-20.

Financial data available through: 2024-12-31.

Coverage by financial measure

Revenue: 10 of 11 periods available· newest 2024-12-31
Operating income: 11 of 11 periods available· newest 2024-12-31
Net income: 11 of 11 periods available· newest 2024-12-31
Operating cash flow: 11 of 11 periods available· newest 2024-12-31
Capital expenditure: 11 of 11 periods available· newest 2024-12-31
Total assets: 10 of 11 periods available· newest 2024-12-31
Total liabilities: 10 of 11 periods available· newest 2024-12-31
Current assets: 10 of 11 periods available· newest 2024-12-31
Current liabilities: 10 of 11 periods available· newest 2024-12-31
Cash and cash equivalents: 10 of 11 periods available· newest 2024-12-31
long term debt: No compatible figures in this window
Shares outstanding: 10 of 11 periods available· newest 2024-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+46.6%

Prior period

USD 464.37 million

2023-01-01 – 2023-12-31
Current period

USD 680.85 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

680852000 − 464370000 = 216482000 USD

464370000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
680852000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Intra-Cellular Therapies, Inc. · 2024-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Year-over-year change in Revenue: 216482000 USD Concept: fundies:Revenue Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 680852000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000162828025006993/itci-20241231.htm#1108071 Filing: 000162828025006993 Input fundies:Revenue: 464370000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000162828025006993/itci-20241231.htm#1108857 Filing: 000162828025006993
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 65 million

Prior period

−USD 139.67 million

2023-01-01 – 2023-12-31
Current period

−USD 74.68 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-74676000 − -139674000 = 64998000 USD

-139674000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-74676000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Intra-Cellular Therapies, Inc. · 2024-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Year-over-year change in Net income: 64998000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -74676000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000162828025006993/itci-20241231.htm#1221617 Filing: 000162828025006993 Input fundies:NetIncome: -139674000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000162828025006993/itci-20241231.htm#1195206 Filing: 000162828025006993
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 51.02 million

Prior period

−USD 124.2 million

2023-01-01 – 2023-12-31
Current period

−USD 73.18 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-73177000 − -124199000 = 51022000 USD

-124199000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-73177000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Intra-Cellular Therapies, Inc. · 2024-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Year-over-year change in Operating cash flow: 51022000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -73177000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000162828025006993/itci-20241231.htm#1265456 Filing: 000162828025006993 Input fundies:OperatingCashFlow: -124199000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000162828025006993/itci-20241231.htm#1266113 Filing: 000162828025006993
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+19.7%

Prior period

USD 269,000

2023-01-01 – 2023-12-31
Current period

USD 322,000

2024-01-01 – 2024-12-31

Exact inputs and evidence

322000 − 269000 = 53000 USD

269000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
322000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Intra-Cellular Therapies, Inc. · 2024-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Year-over-year change in Capital expenditure: 53000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 322000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000162828025006993/itci-20241231.htm#1272877 Filing: 000162828025006993 Input fundies:CapitalExpenditure: 269000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000162828025006993/itci-20241231.htm#1273441 Filing: 000162828025006993
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2024 2024-01-01 – 2024-12-31

Revenue USD 680.85 million 100% of revenue
Operating costs Derived USD 797.57 million 117% of revenue
Operating income −USD 116.72 million −17% of revenue
Tax, interest and other Derived −USD 42.05 million −6.2% of revenue
Net income −USD 74.68 million −11% of revenue

Cash

Operating cash flow −USD 73.18 million −11% of revenue
Capital expenditure USD 322,000 0% of revenue
Free cash flow Derived −USD 73.5 million −11% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2015 Operating loss: operating costs were 115,916% of revenue.
2016 Operating loss: operating costs were 35,860% of revenue.
2017 Operating loss: operating costs were 41,933% of revenue.
2019 Operating loss: operating costs were 254,190% of revenue.
2020 Operating loss: operating costs were 1,114% of revenue.
2021 Operating loss: operating costs were 441% of revenue.
2022 Operating loss: operating costs were 205% of revenue.
2023 Operating loss: operating costs were 134% of revenue.
2024 Operating loss: operating costs were 117% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2015 2015-01-01 – 2015-12-31	91364	105905360 Derived	-105813996	-1020855 Derived	-104793141	-103140560 Derived	Source 2015-01-01 – 2015-12-31: 91364 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -105813996 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -104793141 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -102279965 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 860595 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	330702	118589593 Derived	-118258891	-1832623 Derived	-116426268	-91306191 Derived	Source 2016-01-01 – 2016-12-31: 330702 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -118258891 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -116426268 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -91257227 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 48964 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	245837	103085966 Derived	-102840129	-5066715 Derived	-97773414	-81215241 Derived	Source 2017-01-01 – 2017-12-31: 245837 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -102840129 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -97773414 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -80491812 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 723429 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	60613	154072463 Derived	-154011850	-6289672 Derived	-147722178	-128683636 Derived	Source 2019-01-01 – 2019-12-31: 60613 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -154011850 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -147722178 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -127983241 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 700395 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	22813000	254041000 Derived	-231228000	-4222000 Derived	-227006000	-230340000 Derived	Source 2020-01-01 – 2020-12-31: 22813000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -231228000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -227006000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -230073000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 267000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	83803000	369491000 Derived	-285688000	-1562000 Derived	-284126000	-259869000 Derived	Source 2021-01-01 – 2021-12-31: 83803000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -285688000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -284126000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -259544000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 325000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	250314000	513940000 Derived	-263626000	-7370000 Derived	-256256000	-270964000 Derived	Source 2022-01-01 – 2022-12-31: 250314000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -263626000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -256256000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -270186000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 778000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	464370000	623751000 Derived	-159381000	-19707000 Derived	-139674000	-124468000 Derived	Source 2023-01-01 – 2023-12-31: 464370000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -159381000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -139674000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -124199000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 269000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	680852000	797573000 Derived	-116721000	-42045000 Derived	-74676000	-73499000 Derived	Source 2024-01-01 – 2024-12-31: 680852000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -116721000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -74676000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -73177000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 322000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 680.9M 2024

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Revenue	577301	Revenue: 577301 Open source
20152015-12-31	Revenue	91364	Revenue: 91364 Open source
20162016-12-31	Revenue	330702	Revenue: 330702 Open source
20172017-12-31	Revenue	245837	Revenue: 245837 Open source
20192019-12-31	Revenue	60613	Revenue: 60613 Open source
20202020-12-31	Revenue	22813000	Revenue: 22813000 Open source
20212021-12-31	Revenue	83803000	Revenue: 83803000 Open source
20222022-12-31	Revenue	250314000	Revenue: 250314000 Open source
20232023-12-31	Revenue	464370000	Revenue: 464370000 Open source
20242024-12-31	Revenue	680852000	Revenue: 680852000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

46.6% 2024

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Year over year	No prior comparable period	Revenue: 577301 Open source
20152015-12-31	Year over year	-84.2%	Revenue: 91364 Open source Revenue: 577301 Open source
20162016-12-31	Year over year	262%	Revenue: 330702 Open source Revenue: 91364 Open source
20172017-12-31	Year over year	-25.7%	Revenue: 245837 Open source Revenue: 330702 Open source
20192019-12-31	Year over year	No prior comparable period	Revenue: 60613 Open source
20202020-12-31	Year over year	37,537.1%	Revenue: 22813000 Open source Revenue: 60613 Open source
20212021-12-31	Year over year	267.3%	Revenue: 83803000 Open source Revenue: 22813000 Open source
20222022-12-31	Year over year	198.7%	Revenue: 250314000 Open source Revenue: 83803000 Open source
20232023-12-31	Year over year	85.5%	Revenue: 464370000 Open source Revenue: 250314000 Open source
20242024-12-31	Year over year	46.6%	Revenue: 680852000 Open source Revenue: 464370000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -17.1% 2024

Net margin -11% 2024

Free cash flow margin -10.8% 2024

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Operating margin	-5,367.5%	Operating Income: -30986723 Open source Revenue: 577301 Open source
20152015-12-31	Operating margin	-115,815.9%	Operating Income: -105813996 Open source Revenue: 91364 Open source
20162016-12-31	Operating margin	-35,760%	Operating Income: -118258891 Open source Revenue: 330702 Open source
20172017-12-31	Operating margin	-41,832.6%	Operating Income: -102840129 Open source Revenue: 245837 Open source
20192019-12-31	Operating margin	-254,090.5%	Operating Income: -154011850 Open source Revenue: 60613 Open source
20202020-12-31	Operating margin	-1,013.6%	Operating Income: -231228000 Open source Revenue: 22813000 Open source
20212021-12-31	Operating margin	-340.9%	Operating Income: -285688000 Open source Revenue: 83803000 Open source
20222022-12-31	Operating margin	-105.3%	Operating Income: -263626000 Open source Revenue: 250314000 Open source
20232023-12-31	Operating margin	-34.3%	Operating Income: -159381000 Open source Revenue: 464370000 Open source
20242024-12-31	Operating margin	-17.1%	Operating Income: -116721000 Open source Revenue: 680852000 Open source
20142014-12-31	Net margin	-5,316.4%	Net Income: -30691460 Open source Revenue: 577301 Open source
20152015-12-31	Net margin	-114,698.5%	Net Income: -104793141 Open source Revenue: 91364 Open source
20162016-12-31	Net margin	-35,205.8%	Net Income: -116426268 Open source Revenue: 330702 Open source
20172017-12-31	Net margin	-39,771.6%	Net Income: -97773414 Open source Revenue: 245837 Open source
20192019-12-31	Net margin	-243,713.7%	Net Income: -147722178 Open source Revenue: 60613 Open source
20202020-12-31	Net margin	-995.1%	Net Income: -227006000 Open source Revenue: 22813000 Open source
20212021-12-31	Net margin	-339%	Net Income: -284126000 Open source Revenue: 83803000 Open source
20222022-12-31	Net margin	-102.4%	Net Income: -256256000 Open source Revenue: 250314000 Open source
20232023-12-31	Net margin	-30.1%	Net Income: -139674000 Open source Revenue: 464370000 Open source
20242024-12-31	Net margin	-11%	Net Income: -74676000 Open source Revenue: 680852000 Open source
20142014-12-31	Free cash flow margin	Not reported	Revenue: 577301 Open source
20152015-12-31	Free cash flow margin	-112,889.7%	Revenue: 91364 Open source Operating Cash Flow: -102279965 Open source Capital Expenditure: 860595 Open source
20162016-12-31	Free cash flow margin	-27,609.8%	Revenue: 330702 Open source Operating Cash Flow: -91257227 Open source Capital Expenditure: 48964 Open source
20172017-12-31	Free cash flow margin	-33,036.2%	Revenue: 245837 Open source Operating Cash Flow: -80491812 Open source Capital Expenditure: 723429 Open source
20192019-12-31	Free cash flow margin	-212,303.7%	Revenue: 60613 Open source Operating Cash Flow: -127983241 Open source Capital Expenditure: 700395 Open source
20202020-12-31	Free cash flow margin	-1,009.7%	Revenue: 22813000 Open source Operating Cash Flow: -230073000 Open source Capital Expenditure: 267000 Open source
20212021-12-31	Free cash flow margin	-310.1%	Revenue: 83803000 Open source Operating Cash Flow: -259544000 Open source Capital Expenditure: 325000 Open source
20222022-12-31	Free cash flow margin	-108.2%	Revenue: 250314000 Open source Operating Cash Flow: -270186000 Open source Capital Expenditure: 778000 Open source
20232023-12-31	Free cash flow margin	-26.8%	Revenue: 464370000 Open source Operating Cash Flow: -124199000 Open source Capital Expenditure: 269000 Open source
20242024-12-31	Free cash flow margin	-10.8%	Revenue: 680852000 Open source Operating Cash Flow: -73177000 Open source Capital Expenditure: 322000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -73.2M 2024

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Operating cash flow	Not reported	No source recorded
20152015-12-31	Operating cash flow	-102279965	Operating Cash Flow: -102279965 Open source
20162016-12-31	Operating cash flow	-91257227	Operating Cash Flow: -91257227 Open source
20172017-12-31	Operating cash flow	-80491812	Operating Cash Flow: -80491812 Open source
20192019-12-31	Operating cash flow	-127983241	Operating Cash Flow: -127983241 Open source
20202020-12-31	Operating cash flow	-230073000	Operating Cash Flow: -230073000 Open source
20212021-12-31	Operating cash flow	-259544000	Operating Cash Flow: -259544000 Open source
20222022-12-31	Operating cash flow	-270186000	Operating Cash Flow: -270186000 Open source
20232023-12-31	Operating cash flow	-124199000	Operating Cash Flow: -124199000 Open source
20242024-12-31	Operating cash flow	-73177000	Operating Cash Flow: -73177000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -73.5M 2024

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Free cash flow	Unavailable	No source recorded
20152015-12-31	Free cash flow	-103140560	Operating Cash Flow: -102279965 Open source Capital Expenditure: 860595 Open source
20162016-12-31	Free cash flow	-91306191	Operating Cash Flow: -91257227 Open source Capital Expenditure: 48964 Open source
20172017-12-31	Free cash flow	-81215241	Operating Cash Flow: -80491812 Open source Capital Expenditure: 723429 Open source
20192019-12-31	Free cash flow	-128683636	Operating Cash Flow: -127983241 Open source Capital Expenditure: 700395 Open source
20202020-12-31	Free cash flow	-230340000	Operating Cash Flow: -230073000 Open source Capital Expenditure: 267000 Open source
20212021-12-31	Free cash flow	-259869000	Operating Cash Flow: -259544000 Open source Capital Expenditure: 325000 Open source
20222022-12-31	Free cash flow	-270964000	Operating Cash Flow: -270186000 Open source Capital Expenditure: 778000 Open source
20232023-12-31	Free cash flow	-124468000	Operating Cash Flow: -124199000 Open source Capital Expenditure: 269000 Open source
20242024-12-31	Free cash flow	-73499000	Operating Cash Flow: -73177000 Open source Capital Expenditure: 322000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

16% 2024

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Liabilities / assets	8.1%	Total Liabilities: 10557064 Open source Total Assets: 131111769 Open source
20152015-12-31	Liabilities / assets	1.6%	Total Liabilities: 7860617 Open source Total Assets: 484103528 Open source
20162016-12-31	Liabilities / assets	3.4%	Total Liabilities: 13400956 Open source Total Assets: 388903495 Open source
20172017-12-31	Liabilities / assets	3.6%	Total Liabilities: 17049738 Open source Total Assets: 471486699 Open source
20192019-12-31	Liabilities / assets	22.4%	Total Liabilities: 56179205 Open source Total Assets: 251186476 Open source
20202020-12-31	Liabilities / assets	8.4%	Total Liabilities: 60453570 Open source Total Assets: 717313674 Open source
20212021-12-31	Liabilities / assets	14.7%	Total Liabilities: 72032000 Open source Total Assets: 489922000 Open source
20222022-12-31	Liabilities / assets	13.1%	Total Liabilities: 98710000 Open source Total Assets: 754780000 Open source
20232023-12-31	Liabilities / assets	18.8%	Total Liabilities: 136871000 Open source Total Assets: 728295000 Open source
20242024-12-31	Liabilities / assets	16%	Total Liabilities: 218452000 Open source Total Assets: 1366912000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

6.36× 2024

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Current assets / current liabilities	12.41×	Current Assets: 130986272 Open source Current Liabilities: 10557064 Open source
20152015-12-31	Current assets / current liabilities	77.15×	Current Assets: 483256131 Open source Current Liabilities: 6263512 Open source
20162016-12-31	Current assets / current liabilities	36.86×	Current Assets: 388200116 Open source Current Liabilities: 10532334 Open source
20172017-12-31	Current assets / current liabilities	33.02×	Current Assets: 469215328 Open source Current Liabilities: 14209606 Open source
20192019-12-31	Current assets / current liabilities	6.36×	Current Assets: 230323969 Open source Current Liabilities: 36224019 Open source
20202020-12-31	Current assets / current liabilities	18.75×	Current Assets: 690904482 Open source Current Liabilities: 36853223 Open source
20212021-12-31	Current assets / current liabilities	8.76×	Current Assets: 467281000 Open source Current Liabilities: 53357000 Open source
20222022-12-31	Current assets / current liabilities	8.87×	Current Assets: 737957000 Open source Current Liabilities: 83236000 Open source
20232023-12-31	Current assets / current liabilities	5.41×	Current Assets: 667799000 Open source Current Liabilities: 123545000 Open source
20242024-12-31	Current assets / current liabilities	6.36×	Current Assets: 1307364000 Open source Current Liabilities: 205704000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2015 2015-01-01 – 2015-12-31	−USD 104.79 million Exact value Exact value: -104793141 USD 2015-01-01 – 2015-12-31: -104793141 USD Inspect Net Income Open source Share or cite Citation for Net Income · Intra-Cellular Therapies, Inc. · 2015-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Net Income: -104793141 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -104793141 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000119312518067144/itci-20171231.xml#75952 Filing: 000119312518067144 The citation records this snapshot. The page link may show a newer release later.	−USD 102.28 million Exact value Exact value: -102279965 USD 2015-01-01 – 2015-12-31: -102279965 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Intra-Cellular Therapies, Inc. · 2015-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Operating Cash Flow: -102279965 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -102279965 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000119312518067144/itci-20171231.xml#75121 Filing: 000119312518067144 The citation records this snapshot. The page link may show a newer release later.	USD 860,595 Exact value Exact value: 860595 USD 2015-01-01 – 2015-12-31: 860595 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Intra-Cellular Therapies, Inc. · 2015-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Capital Expenditure: 860595 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 860595 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000119312518067144/itci-20171231.xml#77252 Filing: 000119312518067144 The citation records this snapshot. The page link may show a newer release later.	−USD 103.14 million Calculation and evidence -102279965 − 860595 USD Exact free cash flow: -103140560 USD 2015-01-01 – 2015-12-31: -102279965 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 860595 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Intra-Cellular Therapies, Inc. · 2015-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Free cash flow: -103140560 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -102279965 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000119312518067144/itci-20171231.xml#75121 Filing: 000119312518067144 Input fundies:CapitalExpenditure: 860595 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000119312518067144/itci-20171231.xml#77252 Filing: 000119312518067144 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 116.43 million Exact value Exact value: -116426268 USD 2016-01-01 – 2016-12-31: -116426268 USD Inspect Net Income Open source Share or cite Citation for Net Income · Intra-Cellular Therapies, Inc. · 2016-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Net Income: -116426268 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -116426268 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000119312519054119/itci-20181231.xml#774588 Filing: 000119312519054119 The citation records this snapshot. The page link may show a newer release later.	−USD 91.26 million Exact value Exact value: -91257227 USD 2016-01-01 – 2016-12-31: -91257227 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Intra-Cellular Therapies, Inc. · 2016-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Operating Cash Flow: -91257227 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -91257227 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000119312519054119/itci-20181231.xml#774320 Filing: 000119312519054119 The citation records this snapshot. The page link may show a newer release later.	USD 48,964 Exact value Exact value: 48964 USD 2016-01-01 – 2016-12-31: 48964 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Intra-Cellular Therapies, Inc. · 2016-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Capital Expenditure: 48964 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 48964 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000119312519054119/itci-20181231.xml#776108 Filing: 000119312519054119 The citation records this snapshot. The page link may show a newer release later.	−USD 91.31 million Calculation and evidence -91257227 − 48964 USD Exact free cash flow: -91306191 USD 2016-01-01 – 2016-12-31: -91257227 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 48964 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Intra-Cellular Therapies, Inc. · 2016-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Free cash flow: -91306191 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -91257227 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000119312519054119/itci-20181231.xml#774320 Filing: 000119312519054119 Input fundies:CapitalExpenditure: 48964 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000119312519054119/itci-20181231.xml#776108 Filing: 000119312519054119 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 97.77 million Exact value Exact value: -97773414 USD 2017-01-01 – 2017-12-31: -97773414 USD Inspect Net Income Open source Share or cite Citation for Net Income · Intra-Cellular Therapies, Inc. · 2017-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Net Income: -97773414 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -97773414 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000119312520057888/d863619d10k.htm#1699740 Filing: 000119312520057888 The citation records this snapshot. The page link may show a newer release later.	−USD 80.49 million Exact value Exact value: -80491812 USD 2017-01-01 – 2017-12-31: -80491812 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Intra-Cellular Therapies, Inc. · 2017-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Operating Cash Flow: -80491812 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -80491812 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000119312520057888/d863619d10k.htm#1871532 Filing: 000119312520057888 The citation records this snapshot. The page link may show a newer release later.	USD 723,429 Exact value Exact value: 723429 USD 2017-01-01 – 2017-12-31: 723429 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Intra-Cellular Therapies, Inc. · 2017-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Capital Expenditure: 723429 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 723429 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000119312520057888/d863619d10k.htm#1888342 Filing: 000119312520057888 The citation records this snapshot. The page link may show a newer release later.	−USD 81.22 million Calculation and evidence -80491812 − 723429 USD Exact free cash flow: -81215241 USD 2017-01-01 – 2017-12-31: -80491812 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 723429 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Intra-Cellular Therapies, Inc. · 2017-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Free cash flow: -81215241 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -80491812 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000119312520057888/d863619d10k.htm#1871532 Filing: 000119312520057888 Input fundies:CapitalExpenditure: 723429 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000119312520057888/d863619d10k.htm#1888342 Filing: 000119312520057888 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 155.13 million Exact value Exact value: -155127411 USD 2018-01-01 – 2018-12-31: -155127411 USD Inspect Net Income Open source Share or cite Citation for Net Income · Intra-Cellular Therapies, Inc. · 2018-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Net Income: -155127411 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -155127411 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000119312521055751/d106177d10k.htm#1311448 Filing: 000119312521055751 The citation records this snapshot. The page link may show a newer release later.	−USD 118.17 million Exact value Exact value: -118169113 USD 2018-01-01 – 2018-12-31: -118169113 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Intra-Cellular Therapies, Inc. · 2018-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Operating Cash Flow: -118169113 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -118169113 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000119312521055751/d106177d10k.htm#1429310 Filing: 000119312521055751 The citation records this snapshot. The page link may show a newer release later.	USD 391,268 Exact value Exact value: 391268 USD 2018-01-01 – 2018-12-31: 391268 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Intra-Cellular Therapies, Inc. · 2018-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Capital Expenditure: 391268 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 391268 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000119312521055751/d106177d10k.htm#1438061 Filing: 000119312521055751 The citation records this snapshot. The page link may show a newer release later.	−USD 118.56 million Calculation and evidence -118169113 − 391268 USD Exact free cash flow: -118560381 USD 2018-01-01 – 2018-12-31: -118169113 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 391268 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Intra-Cellular Therapies, Inc. · 2018-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Free cash flow: -118560381 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -118169113 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000119312521055751/d106177d10k.htm#1429310 Filing: 000119312521055751 Input fundies:CapitalExpenditure: 391268 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000119312521055751/d106177d10k.htm#1438061 Filing: 000119312521055751 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 147.72 million Exact value Exact value: -147722178 USD 2019-01-01 – 2019-12-31: -147722178 USD Inspect Net Income Open source Share or cite Citation for Net Income · Intra-Cellular Therapies, Inc. · 2019-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Net Income: -147722178 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -147722178 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000119312522059849/d234590d10k.htm#1243567 Filing: 000119312522059849 The citation records this snapshot. The page link may show a newer release later.	−USD 127.98 million Exact value Exact value: -127983241 USD 2019-01-01 – 2019-12-31: -127983241 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Intra-Cellular Therapies, Inc. · 2019-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Operating Cash Flow: -127983241 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -127983241 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000119312522059849/d234590d10k.htm#1344197 Filing: 000119312522059849 The citation records this snapshot. The page link may show a newer release later.	USD 700,395 Exact value Exact value: 700395 USD 2019-01-01 – 2019-12-31: 700395 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Intra-Cellular Therapies, Inc. · 2019-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Capital Expenditure: 700395 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 700395 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000119312522059849/d234590d10k.htm#1351303 Filing: 000119312522059849 The citation records this snapshot. The page link may show a newer release later.	−USD 128.68 million Calculation and evidence -127983241 − 700395 USD Exact free cash flow: -128683636 USD 2019-01-01 – 2019-12-31: -127983241 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 700395 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Intra-Cellular Therapies, Inc. · 2019-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Free cash flow: -128683636 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -127983241 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000119312522059849/d234590d10k.htm#1344197 Filing: 000119312522059849 Input fundies:CapitalExpenditure: 700395 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000119312522059849/d234590d10k.htm#1351303 Filing: 000119312522059849 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 227.01 million Exact value Exact value: -227006000 USD 2020-01-01 – 2020-12-31: -227006000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Intra-Cellular Therapies, Inc. · 2020-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Net Income: -227006000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -227006000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000119312523055176/d436875d10k.htm#1092359 Filing: 000119312523055176 The citation records this snapshot. The page link may show a newer release later.	−USD 230.07 million Exact value Exact value: -230073000 USD 2020-01-01 – 2020-12-31: -230073000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Intra-Cellular Therapies, Inc. · 2020-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Operating Cash Flow: -230073000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -230073000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000119312523055176/d436875d10k.htm#1272693 Filing: 000119312523055176 The citation records this snapshot. The page link may show a newer release later.	USD 267,000 Exact value Exact value: 267000 USD 2020-01-01 – 2020-12-31: 267000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Intra-Cellular Therapies, Inc. · 2020-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Capital Expenditure: 267000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 267000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000119312523055176/d436875d10k.htm#1281298 Filing: 000119312523055176 The citation records this snapshot. The page link may show a newer release later.	−USD 230.34 million Calculation and evidence -230073000 − 267000 USD Exact free cash flow: -230340000 USD 2020-01-01 – 2020-12-31: -230073000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 267000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Intra-Cellular Therapies, Inc. · 2020-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Free cash flow: -230340000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -230073000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000119312523055176/d436875d10k.htm#1272693 Filing: 000119312523055176 Input fundies:CapitalExpenditure: 267000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000119312523055176/d436875d10k.htm#1281298 Filing: 000119312523055176 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 284.13 million Exact value Exact value: -284126000 USD 2021-01-01 – 2021-12-31: -284126000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Intra-Cellular Therapies, Inc. · 2021-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Net Income: -284126000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -284126000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000162828024006156/itci-20231231.htm#1070101 Filing: 000162828024006156 The citation records this snapshot. The page link may show a newer release later.	−USD 259.54 million Exact value Exact value: -259544000 USD 2021-01-01 – 2021-12-31: -259544000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Intra-Cellular Therapies, Inc. · 2021-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Operating Cash Flow: -259544000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -259544000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000162828024006156/itci-20231231.htm#1160991 Filing: 000162828024006156 The citation records this snapshot. The page link may show a newer release later.	USD 325,000 Exact value Exact value: 325000 USD 2021-01-01 – 2021-12-31: 325000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Intra-Cellular Therapies, Inc. · 2021-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Capital Expenditure: 325000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 325000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000162828024006156/itci-20231231.htm#1168225 Filing: 000162828024006156 The citation records this snapshot. The page link may show a newer release later.	−USD 259.87 million Calculation and evidence -259544000 − 325000 USD Exact free cash flow: -259869000 USD 2021-01-01 – 2021-12-31: -259544000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 325000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Intra-Cellular Therapies, Inc. · 2021-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Free cash flow: -259869000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -259544000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000162828024006156/itci-20231231.htm#1160991 Filing: 000162828024006156 Input fundies:CapitalExpenditure: 325000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000162828024006156/itci-20231231.htm#1168225 Filing: 000162828024006156 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 256.26 million Exact value Exact value: -256256000 USD 2022-01-01 – 2022-12-31: -256256000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Intra-Cellular Therapies, Inc. · 2022-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Net Income: -256256000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -256256000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000162828025006993/itci-20241231.htm#1174902 Filing: 000162828025006993 The citation records this snapshot. The page link may show a newer release later.	−USD 270.19 million Exact value Exact value: -270186000 USD 2022-01-01 – 2022-12-31: -270186000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Intra-Cellular Therapies, Inc. · 2022-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Operating Cash Flow: -270186000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -270186000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000162828025006993/itci-20241231.htm#1266772 Filing: 000162828025006993 The citation records this snapshot. The page link may show a newer release later.	USD 778,000 Exact value Exact value: 778000 USD 2022-01-01 – 2022-12-31: 778000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Intra-Cellular Therapies, Inc. · 2022-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Capital Expenditure: 778000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 778000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000162828025006993/itci-20241231.htm#1274006 Filing: 000162828025006993 The citation records this snapshot. The page link may show a newer release later.	−USD 270.96 million Calculation and evidence -270186000 − 778000 USD Exact free cash flow: -270964000 USD 2022-01-01 – 2022-12-31: -270186000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 778000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Intra-Cellular Therapies, Inc. · 2022-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Free cash flow: -270964000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -270186000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000162828025006993/itci-20241231.htm#1266772 Filing: 000162828025006993 Input fundies:CapitalExpenditure: 778000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000162828025006993/itci-20241231.htm#1274006 Filing: 000162828025006993 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 139.67 million Exact value Exact value: -139674000 USD 2023-01-01 – 2023-12-31: -139674000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Intra-Cellular Therapies, Inc. · 2023-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Net Income: -139674000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -139674000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000162828025006993/itci-20241231.htm#1195206 Filing: 000162828025006993 The citation records this snapshot. The page link may show a newer release later.	−USD 124.2 million Exact value Exact value: -124199000 USD 2023-01-01 – 2023-12-31: -124199000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Intra-Cellular Therapies, Inc. · 2023-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Operating Cash Flow: -124199000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -124199000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000162828025006993/itci-20241231.htm#1266113 Filing: 000162828025006993 The citation records this snapshot. The page link may show a newer release later.	USD 269,000 Exact value Exact value: 269000 USD 2023-01-01 – 2023-12-31: 269000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Intra-Cellular Therapies, Inc. · 2023-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Capital Expenditure: 269000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 269000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000162828025006993/itci-20241231.htm#1273441 Filing: 000162828025006993 The citation records this snapshot. The page link may show a newer release later.	−USD 124.47 million Calculation and evidence -124199000 − 269000 USD Exact free cash flow: -124468000 USD 2023-01-01 – 2023-12-31: -124199000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 269000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Intra-Cellular Therapies, Inc. · 2023-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Free cash flow: -124468000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -124199000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000162828025006993/itci-20241231.htm#1266113 Filing: 000162828025006993 Input fundies:CapitalExpenditure: 269000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000162828025006993/itci-20241231.htm#1273441 Filing: 000162828025006993 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 74.68 million Exact value Exact value: -74676000 USD 2024-01-01 – 2024-12-31: -74676000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Intra-Cellular Therapies, Inc. · 2024-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Net Income: -74676000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -74676000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000162828025006993/itci-20241231.htm#1221617 Filing: 000162828025006993 The citation records this snapshot. The page link may show a newer release later.	−USD 73.18 million Exact value Exact value: -73177000 USD 2024-01-01 – 2024-12-31: -73177000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Intra-Cellular Therapies, Inc. · 2024-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Operating Cash Flow: -73177000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -73177000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000162828025006993/itci-20241231.htm#1265456 Filing: 000162828025006993 The citation records this snapshot. The page link may show a newer release later.	USD 322,000 Exact value Exact value: 322000 USD 2024-01-01 – 2024-12-31: 322000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Intra-Cellular Therapies, Inc. · 2024-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Capital Expenditure: 322000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 322000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000162828025006993/itci-20241231.htm#1272877 Filing: 000162828025006993 The citation records this snapshot. The page link may show a newer release later.	−USD 73.5 million Calculation and evidence -73177000 − 322000 USD Exact free cash flow: -73499000 USD 2024-01-01 – 2024-12-31: -73177000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 322000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Intra-Cellular Therapies, Inc. · 2024-12-31 Intra-Cellular Therapies, Inc. (edgar:1567514) Free cash flow: -73499000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T12:36:01Z Snapshot: ecdc776d7a56a1ab00e5fbc89ac5be0bb5edbc3c5da05d94080c3b82866a350f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1567514?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -73177000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000162828025006993/itci-20241231.htm#1265456 Filing: 000162828025006993 Input fundies:CapitalExpenditure: 322000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1567514/000162828025006993/itci-20241231.htm#1272877 Filing: 000162828025006993 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

142 filings · 3,317 latest values · 3,317 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001567514, 1567514, ITCI, edgar:1567514

Also known as INTRA-CELLULAR THERAPIES, INC., Intra-Cellular Therapies, Inc., Oneida Resources Corp.

Intra-Cellular Therapies, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2024 2024-01-01 – 2024-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation